Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 41

1.

Antipsychotic polypharmacy in psychotic disorders: a critical review of neurobiology, efficacy, tolerability and cost effectiveness.

Lochmann van Bennekom MW, Gijsman HJ, Zitman FG.

J Psychopharmacol. 2013 Apr;27(4):327-36. doi: 10.1177/0269881113477709. Epub 2013 Feb 14. Review.

PMID:
23413275
2.

[Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation].

Llorca PM, Miadi-Fargier H, Lançon C, Jasso Mosqueda G, Casadebaig F, Philippe A, Guillon P, Mehnert A, Omnès LF, Chicoye A, Durand-Zaleski I.

Encephale. 2005 Mar-Apr;31(2):235-46. Review. French.

PMID:
15959450
3.

Antipsychotic polypharmacy in schizophrenia: benefits and risks.

Barnes TR, Paton C.

CNS Drugs. 2011 May;25(5):383-99. doi: 10.2165/11587810-000000000-00000. Review.

PMID:
21476610
4.

Using antipsychotic agents in older patients.

Alexopoulos GS, Streim J, Carpenter D, Docherty JP; Expert Consensus Panel for Using Antipsychotic Drugs in Older Patients.

J Clin Psychiatry. 2004;65 Suppl 2:5-99; discussion 100-102; quiz 103-4. Review.

PMID:
14994733
5.

Switching antipsychotic therapies.

Masand PS, Berry SL.

Ann Pharmacother. 2000 Feb;34(2):200-7. Review. Erratum in: Ann Pharmacother 2000 Apr;34(4):541.

PMID:
10676829
6.

Polypharmacy with second-generation antipsychotics: a review of evidence.

Pandurangi AK, Dalkilic A.

J Psychiatr Pract. 2008 Nov;14(6):345-67. doi: 10.1097/01.pra.0000341890.05383.45. Review.

PMID:
19057237
7.

Clinical effectiveness, tolerability and cost-effectiveness of newer drugs for epilepsy in adults: a systematic review and economic evaluation.

Wilby J, Kainth A, Hawkins N, Epstein D, McIntosh H, McDaid C, Mason A, Golder S, O'Meara S, Sculpher M, Drummond M, Forbes C.

Health Technol Assess. 2005 Apr;9(15):1-157, iii-iv. Review.

8.
9.

Polypharmacy in schizophrenia.

Zink M, Englisch S, Meyer-Lindenberg A.

Curr Opin Psychiatry. 2010 Mar;23(2):103-11. doi: 10.1097/YCO.0b013e3283366427. Review.

PMID:
20051861
10.

The clinical effectiveness and cost-effectiveness of testing for cytochrome P450 polymorphisms in patients with schizophrenia treated with antipsychotics: a systematic review and economic evaluation.

Fleeman N, McLeod C, Bagust A, Beale S, Boland A, Dundar Y, Jorgensen A, Payne K, Pirmohamed M, Pushpakom S, Walley T, de Warren-Penny P, Dickson R.

Health Technol Assess. 2010 Jan;14(3):1-157, iii. doi: 10.3310/hta14030. Review.

11.

Clinical trial-based cost-effectiveness analyses of antipsychotic use.

Polsky D, Doshi JA, Bauer MS, Glick HA.

Am J Psychiatry. 2006 Dec;163(12):2047-56. Review.

PMID:
17151153
12.

Antipsychotic polypharmacy: a comprehensive evaluation of relevant correlates of a long-standing clinical practice.

Correll CU, Gallego JA.

Psychiatr Clin North Am. 2012 Sep;35(3):661-81. doi: 10.1016/j.psc.2012.06.007. Epub 2012 Jul 24. Review.

13.

Antipsychotic polypharmacy or monotherapy?

Gardos G.

Neuropsychopharmacol Hung. 2005 Jun;7(2):72-7. Review.

PMID:
16167458
14.

When is antipsychotic polypharmacy supported by research evidence? Implications for QI.

Gören JL, Parks JJ, Ghinassi FA, Milton CG, Oldham JM, Hernandez P, Chan J, Hermann RC.

Jt Comm J Qual Patient Saf. 2008 Oct;34(10):571-82. Review.

PMID:
18947117
15.

A translational research approach to poor treatment response in patients with schizophrenia: clozapine-antipsychotic polypharmacy.

Honer WG, Procyshyn RM, Chen EY, MacEwan GW, Barr AM.

J Psychiatry Neurosci. 2009 Nov;34(6):433-42. Review.

16.

[Leponex, 10 years after -- a clinical review].

Llorca PM, Pere JJ.

Encephale. 2004 Sep-Oct;30(5):474-91. Review. French.

PMID:
15627052
17.

What do large scale studies of medication in schizophrenia add to our management strategies?

Agius M, Davis A, Gilhooley M, Chapman S, Zaman R.

Psychiatr Danub. 2010 Jun;22(2):323-8. Review.

18.

[Antipsychotics in bipolar disorders].

Vacheron-Trystram MN, Braitman A, Cheref S, Auffray L.

Encephale. 2004 Sep-Oct;30(5):417-24. Review. French.

PMID:
15627046
19.

The efficacy, safety, and tolerability of antipsychotics in the elderly.

Maixner SM, Mellow AM, Tandon R.

J Clin Psychiatry. 1999;60 Suppl 8:29-41. Review.

PMID:
10335669
20.

Formulary decisions and health economics.

Glazer WM.

J Clin Psychiatry. 1998;59 Suppl 19:23-9. Review.

PMID:
9847049
Items per page

Supplemental Content

Write to the Help Desk